Meeting
2017 ASCO Annual Meeting
Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial.
Presenter
Andrew B. Lassman, MD
Columbia University Medical Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01800695
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2003)
DOI
10.1200/JCO.2017.35.15_suppl.2003
Abstract #
2003
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2017 ASCO Annual Meeting
Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM.
Speaker: Brian Michael Alexander, MD, MPH
Videos & Slides
2023 ASCO Annual Meeting
INB-200 phase I study of gene modified autologous gamma-delta (γδ) T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance temozolomide (TMZ).
Speaker: Mina Lobbous, MD, MSPH
Videos & Slides
2022 ASCO Annual Meeting
Phase I study of drug-resistant immunotherapy (DRI) with gene-modified autologous γδ T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance temozolomide (TMZ).
Speaker: Louis B. Nabors, MD
Videos & Slides
2021 ASCO Annual Meeting
Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).
Speaker: Jennifer Foster, MD, MPH